Calidi Biotherapeutics Stock Quote CLDI - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

2.08

Bid

Ask

Volume

27,649

0.00 Day's Range 0.00

0.73 52 Week Range 24.00

Market Cap

27.202M

Previous Close

2.10

Open

Last Trade

805

2.08

(formt)

Last Trade Time

09:16:30

Financial Volume

VWAP

Average Volume (3m)

1,491,422

Shares Outstanding

13,078,022

Dividend Yield

PE Ratio

-0.94

Earnings Per Share (EPS)

-2.23

Revenue

Net Profit

-29.22M

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index. The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index.

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.calidibio.com

Headquarters

Wilmington, Delaware, USA

Founded

Calidi Biotherapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the American Stock Exchange with ticker CLDI. The last closing price for Calidi Biotherapeutics was $2.10. Over the last year, Calidi Biotherapeutics shares have traded in a share price range of $ 0.73 to $ 24.00.

Calidi Biotherapeutics currently has 13,078,022 shares outstanding. The market capitalization of Calidi Biotherapeutics is $27.46 million. Calidi Biotherapeutics has a price to earnings ratio (PE ratio) of -0.94.

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...

Calidi Biotherapeutics Announces Proposed Public Offering

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma.Presented data supporting RTNova (CLD-400), the company’s...

Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences

- RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy - RTNova addresses challenges posed by untargetable and untreatable metastatic...

Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...

Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic immunotherapy utilizing neural stem cells to deliver...

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.04	-1.88679245283	2.12	2.2	1.9	1111835	2.06630131	CS
4	0.41	24.5508982036	1.67	3.89	1.48	3105739	2.62350361	CS
12	0.89	74.7899159664	1.19	3.89	0.73	1491422	2.17281299	CS
26	-0.32	-13.3333333333	2.4	3.89	0.73	1249685	2.07840143	CS
52	-19.62	-90.4147465438	21.7	24	0.73	1007627	2.81474864	CS
156	-43.02	-95.3880266075	45.1	50	0.73	818637	3.16031797	CS
260	-43.02	-95.3880266075	45.1	50	0.73	818637	3.16031797	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AAPYKurv Yield Premium Strategy Apple AAPL ETF	$ 28.21 (0.00%)	111
AAPXT Rex 2X Long Apple Daily Target ETF	$ 36.71 (0.00%)	903
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026	$ 26.5431 (0.00%)	0
AAAUGoldman Sachs Physical Gold ETF Shares	$ 26.015 (0.00%)	4.13k
AAAAlternative Access First Priority CLO Bond ETF	$ 25.1111 (0.00%)	0
AAPYKurv Yield Premium Strategy Apple AAPL ETF	$ 28.21 (0.00%)	111
AAPXT Rex 2X Long Apple Daily Target ETF	$ 36.71 (0.00%)	903
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026	$ 26.5431 (0.00%)	0
AAAUGoldman Sachs Physical Gold ETF Shares	$ 26.015 (0.00%)	4.13k
AAAAlternative Access First Priority CLO Bond ETF	$ 25.1111 (0.00%)	0
MSTZT Rex 2X Inverse MSTR Daily Target ETF	$ 0.9528 (0.00%)	26.57M
FXIiShares China Large Cap	$ 30.77 (0.00%)	6.36M
YINNDirexion Daily FTSE China Bull 3X Shares	$ 29.01 (0.00%)	6.01M
OPTTOcean Power Technologies Inc	$ 0.3405 (0.00%)	5.5M
ETHU2x Ether ETF	$ 12.33 (0.00%)	5.35M